Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Transplant Rev (Orlando). 2019 May 13;33(3):130–136. doi: 10.1016/j.trre.2019.05.001

Table 4.

Reported/registered clinical trials of DCreg, Mreg or Treg in kidney or liver transplantation

Cell type Organ
K (kidney);
L (liver)		 Type of
trial		 Target dose
(range)		 Trial ID
Regulatory DC
 Autologous, blood monocyte-derived DCreg K Phase I/II 106/kg Nantes (ONE STUDY) NCT02252055
 Donor blood monocyte-derived DCreg K Phase I 0.5-5×106/kg
(dose escalation)		 Pittsburgh NCT03164265
 Donor blood monocyte-derived DCreg L Phase I/II 2.5-10×106/kg Pittsburgh NCT03726307
*Regulatory macrophages (Mreg)
 Donor blood monocyte-derived Mreg K Phase I/II 2.5-7.5×106/kg Regensburgh (ONE STUDY) NCT 02085629
Regulatory T cells
 Autologous, polyclonally-expanded Treg K, L Phase I/II 0.5-10×106/kg Charite (Germany) (ONE STUDY) ” NCT02371434 (K);
KCL-Oxford (ONE STUDY) NCT02129881 (K);
KCL NCT02166177 (L)
 Autologous, polyclonal or donor Ag alloreactive Treg K Phase I/II 400±100×106
(TOTAL)		 UCSF NCT02711826
 Autologous, donor Ag-alloreactive Treg K, L Phase I 50-900×106
(TOTAL)		 UCSF (ONE STUDY) NCT02244801 (K);
UCSF NCT02188719 (L);
UCSF NCT02474199(L)
 Autologous, donor alloreactive ‘Tregenriched’ (co-cultured with CoSB) K, L Phase I N/A (K); 0.23-6.37×106/kg (L) MGH NCT02091232 (ONE STUDY) (K);
JAPAN UMIN-000015789 (L)

KCL, King’s College, London; MGH, Massachusetts General Hospital; UCSF, University of California San Francisco

*

For a more complete listing of Treg trials, in organ and bone marrow transplantation, see Kawai et al Human Immunology 2018 [90]